Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Structure–Activity Relationships of Hydroxamate-Based Histone Deacetylase-8 Inhibitors: Reality Behind Anticancer Drug Discovery
Sk. Abdul Amin, Nilanjan Adhikari, Tarun Jha
Future Medicinal Chemistry (2017) Vol. 9, Iss. 18, pp. 2211-2237
Closed Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview
Suvankar Banerjee, Nilanjan Adhikari, Sk. Abdul Amin, et al.
European Journal of Medicinal Chemistry (2018) Vol. 164, pp. 214-240
Closed Access | Times Cited: 97
HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches
Nilanjan Adhikari, Sk. Abdul Amin, Prakruti Trivedi, et al.
European Journal of Medicinal Chemistry (2018) Vol. 157, pp. 1127-1142
Closed Access | Times Cited: 59
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy
Nilanjan Adhikari, Tarun Jha, Balaram Ghosh
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 13, pp. 8827-8869
Closed Access | Times Cited: 44
Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?
Sk. Abdul Amin, Samima Khatun, Shovanlal Gayen, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115594-115594
Closed Access | Times Cited: 18
Targeting histone deacetylases in head and neck squamous cell carcinoma: molecular mechanisms and therapeutic targets
Mengchen Xu, Yiming Hou, Na Li, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects
Prakruti Trivedi, Nilanjan Adhikari, Sk. Abdul Amin, et al.
European Journal of Pharmaceutical Sciences (2018) Vol. 124, pp. 165-181
Closed Access | Times Cited: 55
Discovery of 5-naphthylidene-2,4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines
Kalpana Tilekar, Neha Upadhyay, Niklas Jänsch, et al.
Bioorganic Chemistry (2019) Vol. 95, pp. 103522-103522
Closed Access | Times Cited: 43
Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation
Neha Upadhyay, Kalpana Tilekar, Niklas Jänsch, et al.
Bioorganic Chemistry (2020) Vol. 100, pp. 103934-103934
Open Access | Times Cited: 43
Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity
Prakruti Trivedi, Nilanjan Adhikari, Sk. Abdul Amin, et al.
European Journal of Pharmaceutical Sciences (2019) Vol. 138, pp. 105046-105046
Closed Access | Times Cited: 38
Structure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents
Sk. Abdul Amin, Nilanjan Adhikari, Tarun Jha
Pharmacological Research (2018) Vol. 131, pp. 128-142
Closed Access | Times Cited: 36
Histone deacetylase 3 inhibitors in learning and memory processes with special emphasis on benzamides
Sk. Abdul Amin, Nilanjan Adhikari, Sonali Kotagiri, et al.
European Journal of Medicinal Chemistry (2019) Vol. 166, pp. 369-380
Closed Access | Times Cited: 32
Design, Synthesis, and Biological Evaluation of Novel Quinazolin-4(3H)-one-Based Histone Deacetylase 6 (HDAC6) Inhibitors for Anticancer Activity
Yogesh Mahadu Khetmalis, Ashna Fathima, Markus Schweipert, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 11044-11044
Open Access | Times Cited: 9
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)
Suvankar Banerjee, Balaram Ghosh, Tarun Jha, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 10, pp. 1019-1045
Closed Access | Times Cited: 3
Diverse Classes of HDAC8 Inhibitors: In Search of Molecular Fingerprints that Regulate Activity
Sk. Abdul Amin, Nilanjan Adhikari, Tarun Jha
Future Medicinal Chemistry (2018) Vol. 10, Iss. 13, pp. 1589-1602
Closed Access | Times Cited: 31
Histone deacetylase 8 triggers the migration of triple negative breast cancer cells via regulation of YAP signals
Panpan An, Jiexin Li, Linlin Lu, et al.
European Journal of Pharmacology (2018) Vol. 845, pp. 16-23
Closed Access | Times Cited: 28
Design, synthesis, and anticancer activity of imidazo[2,1-b]oxazole-based RAF kinase inhibitors
Mohammed S. Abdel‐Maksoud, Usama M. Ammar, Mohammed I. El–Gamal, et al.
Bioorganic Chemistry (2019) Vol. 93, pp. 103349-103349
Closed Access | Times Cited: 28
HDAC8 inhibitor attenuates airway responses to antigen stimulus through synchronously suppressing galectin-3 expression and reducing macrophage-2 polarization
Meng-Lu Li, Xinming Su, Yuan Ren, et al.
Respiratory Research (2020) Vol. 21, Iss. 1
Open Access | Times Cited: 26
Synthesis, structure activity relationship and biological evaluation of a novel series of quinoline–based benzamide derivatives as anticancer agents and histone deacetylase (HDAC) inhibitors
Negar Omidkhah, Farzin Hadizadeh, Khalil Abnous, et al.
Journal of Molecular Structure (2022) Vol. 1267, pp. 133599-133599
Closed Access | Times Cited: 14
Designing potential HDAC3 inhibitors to improve memory and learning
Sk. Abdul Amin, Nilanjan Adhikari, Tarun Jha, et al.
Journal of Biomolecular Structure and Dynamics (2018) Vol. 37, Iss. 8, pp. 2133-2142
Closed Access | Times Cited: 26
Development of decision trees to discriminate HDAC8 inhibitors and non-inhibitors using recursive partitioning
Sk. Abdul Amin, Nilanjan Adhikari, Tarun Jha
Journal of Biomolecular Structure and Dynamics (2019) Vol. 39, Iss. 1, pp. 1-8
Closed Access | Times Cited: 22
Selective and Nonselective HDAC8 Inhibitors: a Therapeutic Patent Review
Nilanjan Adhikari, Sk. Abdul Amin, Tarun Jha
Pharmaceutical Patent Analyst (2018) Vol. 7, Iss. 6, pp. 259-276
Closed Access | Times Cited: 21
Exploring structural requirements of HDAC10 inhibitors through comparative machine learning approaches
Arijit Bhattacharya, Sk. Abdul Amin, Prabhat Kumar, et al.
Journal of Molecular Graphics and Modelling (2023) Vol. 123, pp. 108510-108510
Closed Access | Times Cited: 6
HDAC8 As an Emerging Target in Drug Discovery With Special Emphasis on Medicinal Chemistry
S. Rajaraman, Ranjani Balakrishnan, Dhruv Deshmukh, et al.
Future Medicinal Chemistry (2023) Vol. 15, Iss. 10, pp. 885-908
Closed Access | Times Cited: 6
Structural exploration of tetrahydroisoquinoline derivatives as HDAC8 inhibitors through multi-QSAR modeling study
Suvankar Banerjee, Nilanjan Adhikari, Sk. Abdul Amin, et al.
Journal of Biomolecular Structure and Dynamics (2019) Vol. 38, Iss. 5, pp. 1551-1564
Closed Access | Times Cited: 18
Synthesis, Anticancer Activity, Structure–Activity Relationship and Binding Mode of Interaction Studies of Substituted Pentanoic Acids
Sanchita Dutta, Amit Kumar Halder, Nilanjan Adhikari, et al.
Future Medicinal Chemistry (2019) Vol. 11, Iss. 14, pp. 1679-1702
Closed Access | Times Cited: 16
Page 1 - Next Page

Scroll to top